Navigation Links
EPGL Technology Selected by Major Corporation for Development
Date:12/16/2013

IRVINE, Calif., Dec. 16, 2013 /PRNewswire/ -- EP Global Communications, Inc., (OTC Ticker EPGL) makes the following announcement:

In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products.

The Development Agreement was signed last week, being the week of December 8, 2013.

"This is the biggest development for our company in its history,"  said David T. Markus PhD.  "This is just the first of many possible Agreements to come for EPGL and its advanced technologies.  EPGL is a leader in BioMEMS technology and the companies we develop with will become leaders as well in this field for their particular products."

The two companies have signed a confidentiality agreement due to the sensitive and competitive nature of the technology.  Details of the first Development Agreement will remain confidential for now.  However, PwC as custodian for AJW Funds Board membership of EPGL has been apprised of the Agreement and its details.

EPGL currently has over 15 new advanced technologies and corporations in the medical device and consumer electronics fields have sought to enter relationship with the company.  Because of this development, EPGL intends to expand upon and focus on this business model going forward. 

EPGL Management and Team would like to wish all of our shareholders a Merry Christmas, Happy Hanukkah and Happy New Year.

About EP Global Communications, Inc.
EP Global Communications, Inc. is an advanced technology development company for both medical devices and consumer electronics.  EPGL also holds an FDA 510k cleared medical device called the MPD1. The MPD1 is a revolutionary new diagnostic and therapeutic tool for the muscular originated pain in the human body.

Safe Harbor Statement
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


'/>"/>
SOURCE EP Global Communications, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First And Only Skincare To Use Plant And Human Adult Stem Cell Technology Launches
2. Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel
3. Lincor Upgrades Patient Engagement Technology, Launches New Product Portfolio
4. Frost & Sullivan Applauds Definiens Strong Technology Portfolio for the Effective Data Analysis of Histology Images
5. Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and Award Programs - Research Report on BD, Sanofi, GSK, Agilent Technologies, and Align Technology
6. The OR Company Acquires Rights to Baltimore-Based Start-Up Technology
7. Drug Solubility Technology: Spray Drying, Extrusion, and SCF
8. Orcasonix Unveils Innovative Ultrasound Technology Built on Cephasonics cQuest Family of Ultrasound Systems
9. Cincinnati Childrens Issued Patent Covering Individualized Medication Dosing Technology
10. Technology & Innovation Transforming Pharmaceutical Sales Training Programs
11. 3D Printing, the Disruptive Technology for World Manufacturing has a New Patent Granted to Renowned Inventor Donald Spector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... According to a new market research report "Medical Radiation Detection, Monitoring & ... Products (Personal Dosimeters, OSL, Badges), Safety (Apron, Shields, Face Mask, Gloves), End ... to reach USD 1,215.4 Million by 2021 from USD 887.0 Million in ... Continue Reading ... ...
(Date:3/29/2017)... , March 29, 2017  Maxor National Pharmacy ... announced that it has named Leah Bailey ... all divisions of the company. With more ... the previous 8 years focused on health care, Bailey ... her tenure at Prime, Bailey advised the PBM, Specialty, ...
(Date:3/29/2017)... 2017  The Pharmaceutical Care Management Association (PCMA) today ... on patient out-of-pocket spending: ... (CMS), the average amount spent out-of-pocket for drugs continues ... in 2016, down from 23% in 2006. ... a coverage problem. Health plans don,t have unlimited funds ...
Breaking Medicine Technology:
(Date:3/29/2017)... Mt. Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... her patients on early orthodontic treatment and accepting new pediatric patients, with or without ... can help young patients have a better orthodontic outcome and experience. When patients receive ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the University of ... W’81, have made a $10 million gift to establish the Ken Moelis and ... a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
Breaking Medicine News(10 mins):